StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) in a research note issued to investors on Tuesday. The firm issued a sell rating on the biotechnology company’s stock.
Cyclacel Pharmaceuticals Price Performance
Cyclacel Pharmaceuticals stock opened at $0.87 on Tuesday. The firm has a market capitalization of $1.87 million, a P/E ratio of -0.05 and a beta of 0.51. Cyclacel Pharmaceuticals has a 52-week low of $0.75 and a 52-week high of $10.12. The stock has a fifty day moving average price of $1.05 and a two-hundred day moving average price of $1.57.
Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.11. Cyclacel Pharmaceuticals had a negative net margin of 21,963.75% and a negative return on equity of 1,901.11%. During the same quarter in the prior year, the business posted ($6.60) EPS. On average, equities research analysts predict that Cyclacel Pharmaceuticals will post -2.29 EPS for the current fiscal year.
Hedge Funds Weigh In On Cyclacel Pharmaceuticals
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.
Recommended Stories
- Five stocks we like better than Cyclacel Pharmaceuticals
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- 3 Fintech Stocks With Good 2021 Prospects
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.